• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

文拉法辛对映体在接受文拉法辛治疗的犬、大鼠和人类体内的处置情况。

The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine.

作者信息

Wang C P, Howell S R, Scatina J, Sisenwine S F

机构信息

Drug Metabolism Division, Wyeth-Ayerst Research, Princeton, New Jersey 08543.

出版信息

Chirality. 1992;4(2):84-90. doi: 10.1002/chir.530040204.

DOI:10.1002/chir.530040204
PMID:1616828
Abstract

A stereospecific high-performance liquid chromatographic (HPLC) method was developed for the quantitation of the enantiomers of venlafaxine, an antidepressant, in dog, rat, and human plasma. The procedure involves derivatization of venlafaxine with the chiral reagent, (+)-S-naproxen chloride, and a postderivatization procedure. The method was linear in the range of 50 to 5,000 ng of each enantiomer per ml of plasma. No interference by endogenous substances or known metabolites of venlafaxine occurred. Studies to characterize the disposition of the enantiomers of venlafaxine were conducted in dog, rat, and human, following oral administration of venlafaxine. The Cmax, area under the curve (AUC) and (S)/(R) concentration ratios of the (R)- and (S)-enantiomers were compared. In rats, the mean plasma ratio of (S)-venlafaxine to that of (R)-venlafaxine over 0.5 to 6.0 h varied from 2.97 to 8.50 with a mean value of 5.51 +/- 2.45. The Cmax, AUC0-infinity, and t 1/2 values of the (R)- and (S)-enantiomers in dogs were not significantly different from one another (P greater than 0.1). The mean ratios [(S)/(R)] of enantiomers of venlafaxine in human over a 2 to 6 h interval ranged from 1.33 to 1.35 with an overall ratio of 1.34 +/- 0.26 (n = 12). These ratios of the enantiomers [(S)/(R)] were not statistically different from unity (P greater than 0.1) indicating that the disposition of venlafaxine enantiomers in humans is not stereoselective and is more similar to that in dogs than that in rats.

摘要

建立了一种立体专一性高效液相色谱(HPLC)法,用于定量测定犬、大鼠和人血浆中抗抑郁药文拉法辛对映体的含量。该方法包括用手性试剂(+)-S-萘普生氯对文拉法辛进行衍生化以及衍生化后处理步骤。该方法在每毫升血浆中每种对映体50至5000 ng的范围内呈线性。未出现内源性物质或文拉法辛已知代谢物的干扰。在犬、大鼠和人身上口服文拉法辛后,进行了文拉法辛对映体处置特征的研究。比较了(R)-和(S)-对映体的Cmax、曲线下面积(AUC)以及(S)/(R)浓度比。在大鼠中,0.5至6.0小时内(S)-文拉法辛与(R)-文拉法辛的平均血浆比值在2.97至8.50之间变化,平均值为5.51±2.45。犬体内(R)-和(S)-对映体的Cmax、AUC0至无穷大以及t 1/2值彼此之间无显著差异(P大于0.1)。在人类中,文拉法辛对映体在2至6小时内的平均比值[(S)/(R)]在1.33至1.35之间,总体比值为1.34±0.26(n = 12)。这些对映体比值[(S)/(R)]与1无统计学差异(P大于0.1),表明文拉法辛对映体在人体内的处置无立体选择性,且与犬体内的情况比与大鼠体内的情况更相似。

相似文献

1
The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine.文拉法辛对映体在接受文拉法辛治疗的犬、大鼠和人类体内的处置情况。
Chirality. 1992;4(2):84-90. doi: 10.1002/chir.530040204.
2
Development and validation of a HPLC-MS/MS method for the determination of venlafaxine enantiomers and application to a pharmacokinetic study in healthy Chinese volunteers.用于测定文拉法辛对映体的HPLC-MS/MS方法的建立与验证及其在健康中国志愿者体内的药代动力学研究中的应用。
Biomed Chromatogr. 2011 Mar;25(3):412-6. doi: 10.1002/bmc.1464.
3
Pharmacokinetics of reboxetine enantiomers in the dog.瑞波西汀对映体在犬体内的药代动力学。
Chirality. 1997;9(3):303-6. doi: 10.1002/(SICI)1520-636X(1997)9:3<303::AID-CHIR17>3.0.CO;2-R.
4
Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability.文拉法辛对映体的稳态浓度:基于模型的患者间变异性分析。
Eur J Clin Pharmacol. 2002 Aug;58(5):323-31. doi: 10.1007/s00228-002-0473-2. Epub 2002 Jun 25.
5
Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatment.慢性药物治疗后肝性脑病大鼠中 Venlafaxine 对映体的处置情况。
Chirality. 2002 May 5;14(4):347-50. doi: 10.1002/chir.10088.
6
Determination of felodipine enantiomers using chiral stationary phase liquid chromatography and gas chromatography/mass spectrometry, and the study of their pharmacokinetic profiles in human and dog.
Biomed Chromatogr. 1993 Mar-Apr;7(2):99-103. doi: 10.1002/bmc.1130070211.
7
Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma.基于Chiralpak手性液相色谱法测定大鼠血浆中(±)-DRF 2725对映体的方法开发与验证:血浆中瑞格列扎(S(-)-DRF 2725)未发生对映体转化。
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 25;809(1):23-30. doi: 10.1016/j.jchromb.2004.05.030.
8
Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.大鼠和犬体内双异丙吡胺对映体代谢的立体选择性
Drug Metab Dispos. 1982 Mar-Apr;10(2):116-21.
9
Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in human plasma by HPLC-ESI/MS using a vancomycin chiral column.使用万古霉素手性柱通过HPLC-ESI/MS对人血浆中文拉法辛和O-去甲基文拉法辛对映体进行同时立体选择性分析。
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 May 1;850(1-2):183-9. doi: 10.1016/j.jchromb.2006.11.021. Epub 2006 Nov 30.
10
Stereoselective and species-dependent kinetics of reboxetine in mouse and rat.
Chirality. 1995;7(4):285-9. doi: 10.1002/chir.530070416.

引用本文的文献

1
Chirality of antidepressive drugs: an overview of stereoselectivity.抗抑郁药物的手性:立体选择性概述
Asian Biomed (Res Rev News). 2022 Apr 29;16(2):55-69. doi: 10.2478/abm-2022-0008. eCollection 2022 Apr.
2
Multiple-reaction monitoring (MRM) LC-MS/MS quantitation of venlafaxine and its O-desmethyl metabolite for a preclinical pharmacokinetic study in rabbits.用于兔类临床前药代动力学研究的文拉法辛及其 O-去甲基代谢物的多重反应监测(MRM)LC-MS/MS 定量分析。
Sci Rep. 2022 Jun 4;12(1):9322. doi: 10.1038/s41598-022-13389-6.
3
Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk.
文拉法辛及O-去甲基文拉法辛在人乳中的分布与排泄
Br J Clin Pharmacol. 1998 May;45(5):459-62. doi: 10.1046/j.1365-2125.1998.00710.x.
4
Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.新型抗抑郁药的代谢。药理学与药代动力学影响概述。
Clin Pharmacokinet. 1998 Apr;34(4):281-302. doi: 10.2165/00003088-199834040-00002.
5
Drug treatment of depression in the 1990s. An overview of achievements and future possibilities.20世纪90年代抑郁症的药物治疗。成就与未来可能性概述。
Drugs. 1996 Nov;52(5):625-38. doi: 10.2165/00003495-199652050-00001.
6
Venlafaxine. A review of its pharmacology and therapeutic potential in depression.文拉法辛。其药理学及在抑郁症治疗中的潜在作用综述。
Drugs. 1995 Feb;49(2):280-94. doi: 10.2165/00003495-199549020-00010.